1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Brooks Laboratories Limited

Brooks Laboratories Limited

61.57
INR
+0.03
(+0.05%)
4.50EPS
15.32P/E
2.03BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
43.5
43.47
40.82
29.35
28.42
39.73
38.88
30.88
36.12
25.29
30.84
30.68
28.98
28.34
Basic EPS, GAAP
3.69
4.83
5.42
0.85
-7.05
-10.69
-13.71
-7.77
-7.74
-8.46
-7.65
-3.72
8.35
4.5
Free Cash Flow per Basic Share
4.42
-9.12
-14.18
-4.11
-6.08
-4.27
-6.73
-0.46
-24.32
-6.06
-4
0.64
1.96
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
57.29
56.84
64.54
65.44
58.4
53.64
39.45
31.73
35.07
29.65
24.99
33.3
41.64
- -
Tangible Book Value per Share
57.29
56.84
64.54
65.44
58.4
53.45
39.34
31.45
34.82
29.57
24.96
33.3
41.64
- -
Basic Weighted Avg Shares
20
20
20
20
20
14
18
25
25
25
26
27
29
29
Sales/Revenue/Turnover
853
852
800
575
557
550
691
770
901
625
790
822
854
832
Operating Margin (%)
9.02
7.22
12.79
5.86
-27.59
-22
-13.37
-8.57
-24.09
-53.7
1.83
7.94
6.41
5.03
Depreciation Expense
8
11
12
17
64
65
66
71
74
70
18
16
16
16
Net Income, GAAP
72
95
106
17
-138
-148
-244
-194
-193
-209
-196
-100
246
132
Effective Tax Rate (%)
4.38
8.53
1.71
32.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
8.49
11.11
13.29
2.9
-24.79
-26.9
-35.26
-25.15
-21.44
-33.44
-24.8
-12.13
28.79
15.88
Working Capital
367
326
16
-24
-98
-157
-79
-163
123
-54
80
110
156
- -
LT Debt
- -
- -
3
107
166
139
119
144
101
6
4
14
21
- -
Total Equity
1,123
1,114
1,265
1,283
1,145
1,052
984
791
1,343
740
656
981
1,227
- -
Return on Invested Capital (%)
6.61
8.41
8.69
1.5
- -
- -
- -
- -
- -
- -
- -
- -
5
- -
Return on Capital (%)
6.69
8.61
9.31
1.65
- -
- -
- -
- -
- -
- -
- -
- -
21.36
- -
Return on Common Equity (%)
6.65
8.46
8.94
1.31
-11.38
-13.48
-23.95
-21.82
-23.18
-25.88
-28.08
-12.18
22.27
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
64
- -
LT Borrowings
- -
12
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
2,364
1,104
2,031

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
374
- -
Cash, Cash Equivalents & STI
- -
79
- -
Accounts Receivable, Net
- -
161
- -
Inventories
- -
110
- -
Total Current Liabilities
- -
218
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
64
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.46%
17.61%
25.03%
Free Cash Flow
510.64%
1,033.57%
239.75%
Net Income, GAAP
-135.58%
-78.83%
-346.65%
Sales/Revenue/Turnover
2.52%
4.13%
3.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
179
208
205
233
822
2026
255
235
166
202
854
2027
230
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.94
-1.51
-0.82
-0.54
-3.72
2026
3.25
2.71
1.87
0.52
8.35
2027
-0.61
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Prashant Rathi
Full Time Employees
347
Sector
Health technology
Industry
Pharmaceuticals: major
Address
201, The Summit Business Park Mumbai MA India 400093
IPO Date
Sep 2, 2011
Website
brookslabs.net
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Brooks Laboratories Limited (BROOKS.NS), a research-driven pharmaceutical contract development and manufacturing organization (CDMO), manufactures sterile injectables and oral dosage forms for pharmaceutical companies in India and internationally. The company offers dry powder injections, liquid injections, general injectables, Beta Lactam tablets, Beta Lactam injections and suspensions, oral suspensions, eye/ear drops, and cephalosporin products; it specializes in critical care formulations including carbapenems through its joint venture subsidiary Brooks SteriScience Limited. Founded in 2002 and headquartered in Mumbai, India, Brooks Laboratories operates WHO-GMP certified manufacturing facilities in Baddi, Himachal Pradesh, and Vadodara, Gujarat, with accreditations from regulatory authorities in Nigeria, Cambodia, Ivory Coast, Yemen, Vietnam, Syria, and the Democratic Republic of Congo. The company exports to markets including Venezuela, Mauritius, Colombia, Uzbekistan, Kosovo, Kenya, Latin America, and other regions in the Rest of World (ROW) and semi-regulated countries. In recent developments, Brooks Laboratories continues expansion through strategic alliances for product registrations in global markets and maintains its carbapenem business via the SteriScience joint venture, which received USFDA approval for the Vadodara facility and focuses on penetrating regulated markets such as the US, Europe, Canada, Australia, and India.